1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
LOI deadlines: June 22, 2026 and November 23, 2026; portal closes 23:59 CET on deadline day.
"Advancing Cancer Research in Sub-Saharan Africa" is currently closed and not accepting applications.
Advancing Cancer Research in Sub-Saharan Africa is a grant from the Rising Tide Foundation for Clinical Cancer Research (RTFCCR) that supports clinical cancer research projects in Uganda and Kenya with the potential for rapid patient impact and long-term capacity building. The foundation accepts Letters of Intent on a rolling basis, with deadlines three times per year; an upcoming LOI deadline is June 22, 2026.
Applications are reviewed by an independent Grant Review Committee that includes scientific peer reviewers, a patient partner, and a biostatistician. Eligible applicants should be based in Uganda or Kenya and committed to clinical cancer research. Final funding decisions are made by the RTFCCR Board of Directors three times annually.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Clinical Cancer Research How to Apply - Rising Tide Foundation Upcoming Deadline: June 22nd, 2026 Grants Management System: New to the Rising Tide Foundation? Please register before applying. Letters of Intent (LOIs) are accepted on a rolling basis, with deadlines for internal assessment three times per year.
LOIs must be submitted through our application portal, SmartSimple. The upcoming deadlines: Please note that the portal will close at 23:59 CET on the deadline day. Before applying, please read our Terms and Conditions .
In case of any questions, please contact rtfccrteam@risingtide. ch . LOIs that best meet our funding criteria will be invited to submit a full application.
Detailed instructions and deadlines will be provided following the LOI review. Full applications are assessed by a Grant Review Committee (GRC), an independent panel of external experts that includes scientific peer reviewers, a patient partner, and a biostatistician.
Following that evaluation, the highest-ranking applications are scored according to their strategic fit to RTFCCR portfolio, based on the following criteria: Patient community perception Researcher and team reputation Recommendations from the GRC and the RTFCCR Advisory Board are submitted to the Rising Tide Board of Directors for final funding approval.
Once the Board of Directors approves, the award recipients will be notified within a month of the board meeting. Board meetings occur three times a year. Patient partners involved in designing the application for a new research project can be financially supported via the pre-application grant.
RTFCCR invites academic institutions and not-for-profit organizations to collaborate on innovative, patient-centered clinical trials. Our mission is to improve cancer patients’ treatment options and quality of life by funding studies focused on detection, treatment, and implementation. We support phase I to phase III interventional clinical trials but do not fund basic research, phase IV trials, or observational studies.
Funding is available to institutions worldwide where effective grant oversight is feasible. The interventional clinical trial can be an early—to—late—stage clinical trial (Phase 1, 2, and 3) with a patient partner involvement in the study protocol design. Only applications aimed at detecting and intervening in early cancer (pre-cancerous changes) can also be considered at the pre-clinical validation stage.
Pharmaceutical agents used in the study can be generic (off-patent repurposing), registered for this indication, or under development by an academic institution. Clinical trials testing immunotherapies should be discussed with RTFCCR before application submission. Final selection will be contingent on scientific review, strategic portfolio fit, and availability of funds.
Scoring criteria used to review proposals for this grant.
According to the current listing, eligibility includes: Applicants should be from Uganda and Kenya, committed to clinical cancer research with potential for rapid patient impact and capacity building. Confirm the full requirements in the official notice before applying.
The published deadline was June 22, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Advancing Cancer Research in Sub-Saharan Africa is funded by Rising Tide Foundation for Clinical Cancer Research. Verify program details on the funder's official page before applying.
This listing is flagged as international in scope. Check the official notice for country-specific restrictions before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
CDMRP reissued the FY26 BCRP Breakthrough Award Levels 1 and 2 and the Clinical Research Extension Award on September 3, 2026, with a November 4 pre-application deadline and a November 18 full application deadline. Round one closed July 8. The arithmetic across both windows accounts for nearly the entire FY26 appropriation — which tells you what kind of second chance this is.
Read articleNOT-OD-26-098 consolidates NIH career development awards into four parent NOFOs (KR1, KC1, KS1, KT1), eliminates the Data Management and Sharing Plan for K applications, and stops supporting K awards that let the awardee lead their own clinical trial. The RFI closes September 30, 2026; the new structure hits due dates on or after October 12, 2027.
Read articleNIH released a draft policy on August 27, 2026 that would require every NIH-supported clinical study to offer participants a plain-language summary of results — clinical trials within one year of completion, all other clinical research by the end of the funding period. It covers observational and behavioral research that ClinicalTrials.gov never touched. Here is the scope, the four requirements nobody has budgeted for, and what to say before the October 26 deadline.
Read article